NCT05929807: An ongoing trial by Ascendis Pharma Growth Disorders A/S
This trial is ongoing. It must report results 14 years, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05929807 |
|---|---|
| Title | A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents With Achondroplasia |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 21, 2023 |
| Completion date | Jan. 31, 2039 |
| Required reporting date | Jan. 31, 2040, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |